Hannah Clarke

As the year comes to a close, we revisit some of this year’s top content on diversity, equity, and inclusion.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

As the year comes to a close, we revisit some of this year’s top content on kidney cancer.

"The previous group who had looked at this saw a 15% adherence to the AUA guidelines up to 2013. We're doing better, but not much better," says Megan Prunty, MD.

“Even though we set some priority areas, we also allow practicing urologists to make suggestions for things that they want to know about,” says Amanda North, MD.

Dr. Van Kuiken discusses 2022 milestones in FPMRS and looks ahead to what might be on the horizon for the field in the coming year.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

“The bottom line is that [gender parity] starts with sponsorship and bringing women to the table in academic leadership positions so that our voices can be heard,” says Bridget Lang Findlay, MD.

"I am prepared and excited to be fully immersed in the health policy work of the AUA as the 2023 Gallagher Scholar," says Denise Asafu-Adjei, MD, MPH.

The clinical research program seeks to increase the number of URiM medical students entering the field of urology.

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

Amanda North, MD, discusses the AUA census in depth, specifically highlighting the data collected on residents and fellows.

The study found pathogenic or likely pathogenic variants in DNA damage repair genes and HOXB13 to be more frequently observed in Black men with a family history of cancer.

The median DOR among the 15 patients in the study was 24.4 months (range, 10.1 to 30.7 months).

"Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.

Risk of tumor recurrence in the BLC Registry group was significantly lower than in patients who received WLC alone.

The collaboration between Streamline Scientific and UroGPO will help deliver PCR technology to UroGPO members.

“To our knowledge, this study represents the first time a significant association has been demonstrated between concurrent and adjuvant ADT sequencing and overall survival rates among prostate cancer patients," says Amar Kishan, MD.

The pharmacokinetic drug GEMTESA, developed by Urovant Sciences, was given to adult patients as a single 75-mg dose in a phase 1 study.

“I think a clinical trial like this that is funded by the NIH and taxpayer dollars will hopefully provide an unbiased answer of whether it works and who it works in,” says Ranjith Ramasamy, MD.

A retrospective multi-center trial assessed the safety and feasibility of antegrade administration of Jelmyto in patients with low-grade UTUC.

The phase 3 EAGLE-2 and EAGLE-3 studies looked at outcomes for gepotidacin, an investigational agent for the treatment of uncomplicated urinary tract infection.

"These technologies have the potential to provide an advantageous and patient-centered solution for the gap between expectant management and urologic intervention for symptomatic ureteral stones,” says M. Kennedy Hall, MD, MHS.

Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.

Using administrative claims data, investigators analyzed the opioid prescriptions filled for vasectomies before and after the expansion of Blue Cross Blue Shield of Michigan's modifier 22 program.

The team of investigators used the COST-FACIT tool to take into account both the time and money lost to treatment.

"If men were aware that just because they have no symptoms doesn’t necessarily mean they are cancer free, then more might take up offers for tests," says Vincent Gnanapragasam, MD.

“It doesn’t necessarily mean that you have cancer. But the more you smoke, the more mutations accumulate in your cells, and the more you increase your risk for developing cancer," said study author Marcos Díaz-Gay, PhD.

“Our work indicates that these genetic signatures may prove to be tremendously valuable in predicting immunotherapy response in patients with bladder cancer, but also other tumor types," says Dan Theodorescu, MD, PhD.